Crossmark

A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC)

Crossref DOI link: https://doi.org/10.1186/s13063-025-08726-9

Published Online: 2025-02-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Arora, Adhip

Seenu, V.

Parshad, Rajinder

Bansal, V. K.

Dhar, Anita

Mathur, Sandeep

Tanwar, Pranay

Mishra, Piyush

Kataria, Kamal

Suhani,

Gogia, Ajay

Kumar, Brijesh

Haresh, K. P.

Mallick, Supriya

Saini, Surendra Kumar

Mishra, Ashutosh

Bansal, Babul

Sharma, Jyoti

Saikia, Jyoutishman

Rangarajan, Krithika

Dhamija, Ekta

Prasad, Chandra Prakash

Shamin, Shamim Ahmed

Agastm, Sourabh

Kalra, Kaushal

Vishvam, Divvay

Mani, Kalaivani

Kumar, Akash

Bakhshi, Sameer

Batra, Atul https://orcid.org/0000-0002-1934-8408
Funding

Funding for this research was provided by:

Indian Council of Medical Research
License Information

Text and Data Mining valid from 2025-02-27

Version of Record valid from 2025-02-27
More Information

Article History

Received: 22 August 2024

Accepted: 13 January 2025

First Online: 27 February 2025

Declarations

:

: Trial protocol has been approved by the institute ethics committee for postgraduate research at All India Institute of Medical Sciences; Ref. No.: AIIMSA00540/18.01.2024, RT-39/21.02.2024.

: Not applicable.Competing interests {28}The authors declare no competing interests.

Document is current

Any future updates will be listed below